| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2018-08-13 | Orchard Therapeutics (UK) | $150 Million | series C financing round | ArrowMark Partners (USA - CO) Cormorant Asset Management (USA - MA) Foresite Capital (USA - NY) RA Capital Management (USA - MA) Perceptive Advisors (USA - NY) RTW Investments (USA - NY) Venrock (USA - CA) Foresite Capital (USA - NY) Sphera Global Healthcare (Spain) Medison Ventures Driehaus Capital Management (USA - IL) Ghost Tree Capital Group (USA - NY) Temasek (Singpore) Baillie Gifford (UK) Cowen Healthcare (USA - NY) Agent Capital (USA - MA) | Rare diseases - Genetic diseases | Series C financing round |
| 2018-08-06 | Pharmaxis (Australia) | A$24 million (£13.4 million - €15.35 million) | financing round | Arix Bioscience (UK) BVF Partners (USA - CA) other existing shareholders | Fibrotic diseases - Inflammatory diseases | Financing round |
| 2018-07-31 | AC Immune (Switzerland) | $117.5 million | private placement | Neurological diseases - CNS diseases | Private placement | |
| 2018-07-23 | Azafaros (The Netherlands) | seed financing round | BioGeneration Ventures (The Netherlands) | Rare diseases - Genetic diseases - Metabolic diseases | Financing round | |
| 2018-07-06 | Oncologie (USA - MA - China) | $16.5 million | seed financing round | Nan Fung Life Sciences (China) Pivotal bioVenture Partners China Fund (China) China Merchant Bank Investments (China) Volcanics Ventures (China) | Cancer - Oncology | Financing round |
| 2018-06-25 | Avrobio (USA - MA) | $114.7 million | IPO | Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases | IPO | |
| 2018-02-05 | Metrion Biosciences (UK) | £200 000 | grant | Innovate UK Biomedical Catalyst Feasibility Award scheme (UK) | Autoimmune diseases - Neurodegenerative diseases | Grant |
| 2018-02-02 | Viking Therapeutics (USA - PA) | $55 million | private placement | Endocrinological diseases - Metabolic diseases | Private placement | |
| 2018-02-02 | Medivir (Sweden) | 155 million SEK (€ 15.75 million) | Infectious diseases | Private placement | ||
| 2018-02-01 | Avrobio (USA - MA) | $60 million | series B financing round | Cormorant Asset Management and Surveyor Capital (a Citadel company), and included participation by Aisling, Brace Pharma Capital, Eventide Asset Management and Morningside, along with existing investors Atlas Venture, SV Health Investors and Clarus Ventures. | Cancer - Oncology - Rare diseases - Genetic diseases | Series B financing round |
| 2018-01-29 | Audentes Therapeutics (USA - CA) | $231.4 million | private placement | Rare diseases - Genetic diseases | Private placement | |
| 2018-01-23 | Tmunity Therapeutics (USA - PA) | $ 100 million | series A financing round | Ping An Ventures (China) Parker Institute for Cancer Immunotherapy (USA - CA) Gilead Sciences (USA - CA) Be The Match BioTherapies University of Pennsylvania (USA - PA) Lilly Asia Ventures (China) | Cancer - Oncology - Autoimmune diseases - Infectious diseases | Series A financing round |
| 2018-01-23 | Skyhawk Therapeutics (USA - MA) | $ 8 million | financing round | Tim Disney, the Duke of Bedford, Alexandria Venture Investments (USA - MA) and other undisclosed private investors | Cancer - Oncology - Neurological diseases | Financing round |
| 2018-01-22 | Avexis (USA - IL) | $431.9 million | private placement | Rare diseases - Genetic diseases - Neuromuscular diseases | Private placement | |
| 2018-01-16 | Arbutus Biopharma (Canada) | US$116.4 million | private placement | Roivant Sciences (CH - USA) | Infectious diseases | Private placement |
| 2018-01-05 | Advicenne (France) | €27.8 million | IPO | Rare diseases - Genetic diseases - Pediatric diseases | IPO | |
| 2018-01-04 | Enterome Bioscience (France) | €40 million | loan | European Investment Bank (EIB) | Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology | Loan |
| 2018-01-04 | Enterome Bioscience (France) | €32 million ($38.5 million) | series D financing round | BMS (USA - NY) Principia SGR (Italy) Health For Life Capital (Seventure) (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) Omnes Capital (France) | Liver diseases - Hepatic diseases - Inflammatory diseases - Digestive diseases - Cancer - Oncology | Series D financing round |
| 2018-01-04 | Acticor Biotech (France) | €3.9 million | financing round | Primer Capital (Russia) Anaxago (France) CapDecisif Management (France) private investors | Cerebrovascular diseases | Financing round |
| 2017-12-29 | Armo BioScience | IPO | Cancer - Oncology | IPO |
